126 related articles for article (PubMed ID: 30579799)
1. Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment.
Kuroda S; Kobashi Y; Oi T; Kawabe K; Shiozawa F; Okumura-Kitajima L; Sugisaki-Kitano M; Io F; Yamamoto K; Kakinuma H
Bioorg Med Chem; 2019 Jan; 27(2):394-409. PubMed ID: 30579799
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Structure-Activity Relationship of C-Phenyl D-Glucitol (TP0454614) Derivatives as Selective Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitors.
Kuroda S; Kobashi Y; Kawamura M; Kawabe K; Shiozawa F; Hamada M; Shimizu Y; Okumura-Kitajima L; Koretsune H; Kimura K; Yamamoto K; Kakinuma H
Chem Pharm Bull (Tokyo); 2020; 68(7):635-652. PubMed ID: 32611999
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes.
Kuroda S; Kobashi Y; Oi T; Amada H; Okumura-Kitajima L; Io F; Yamamto K; Kakinuma H
Bioorg Med Chem Lett; 2018 Dec; 28(22):3534-3539. PubMed ID: 30297284
[TBL] [Abstract][Full Text] [Related]
4. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of thiophene-C-glucosides as sodium-dependent glucose cotransporter 2 inhibitors.
Sakamaki S; Kawanishi E; Koga Y; Yamamoto Y; Kuriyama C; Matsushita Y; Ueta K; Nomura S
Chem Pharm Bull (Tokyo); 2013; 61(10):1037-43. PubMed ID: 24088695
[TBL] [Abstract][Full Text] [Related]
6. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.
Kakinuma H; Oi T; Hashimoto-Tsuchiya Y; Arai M; Kawakita Y; Fukasawa Y; Iida I; Hagima N; Takeuchi H; Chino Y; Asami J; Okumura-Kitajima L; Io F; Yamamoto D; Miyata N; Takahashi T; Uchida S; Yamamoto K
J Med Chem; 2010 Apr; 53(8):3247-61. PubMed ID: 20302302
[TBL] [Abstract][Full Text] [Related]
7. SGL5213, a novel and potent intestinal SGLT1 inhibitor, suppresses intestinal glucose absorption and enhances plasma GLP-1 and GLP-2 secretion in rats.
Io F; Gunji E; Koretsune H; Kato K; Sugisaki-Kitano M; Okumura-Kitajima L; Kimura K; Uchida S; Yamamoto K
Eur J Pharmacol; 2019 Jun; 853():136-144. PubMed ID: 30878385
[TBL] [Abstract][Full Text] [Related]
8. SGLT-1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure.
Ho HJ; Kikuchi K; Oikawa D; Watanabe S; Kanemitsu Y; Saigusa D; Kujirai R; Ikeda-Ohtsubo W; Ichijo M; Akiyama Y; Aoki Y; Mishima E; Ogata Y; Oikawa Y; Matsuhashi T; Toyohara T; Suzuki C; Suzuki T; Mano N; Kagawa Y; Owada Y; Katayama T; Nakayama T; Tomioka Y; Abe T
Physiol Rep; 2021 Dec; 9(24):e15092. PubMed ID: 34921520
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors.
Xu G; Gaul MD; Kuo GH; Du F; Xu JZ; Wallace N; Hinke S; Kirchner T; Silva J; Huebert ND; Lee S; Murray W; Liang Y; Demarest K
Bioorg Med Chem Lett; 2018 Nov; 28(21):3446-3453. PubMed ID: 30268701
[TBL] [Abstract][Full Text] [Related]
10. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors.
Chu KF; Song JS; Chen CT; Yeh TK; Hsieh TC; Huang CY; Wang MH; Wu SH; Yao CH; Chao YS; Lee JC
Bioorg Chem; 2019 Mar; 83():520-525. PubMed ID: 30469144
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
Li Y; Shi Z; Chen L; Zheng S; Li S; Xu B; Liu Z; Liu J; Deng C; Ye F
J Med Chem; 2017 May; 60(10):4173-4184. PubMed ID: 28447791
[TBL] [Abstract][Full Text] [Related]
13. Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents.
Du F; Hinke SA; Cavanaugh C; Polidori D; Wallace N; Kirchner T; Jennis M; Lang W; Kuo GH; Gaul MD; Lenhard J; Demarest K; Ajami NJ; Liang Y; Hornby PJ
J Pharmacol Exp Ther; 2018 Jun; 365(3):676-687. PubMed ID: 29674332
[TBL] [Abstract][Full Text] [Related]
14. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach.
Yamaguchi K; Kato M; Suzuki M; Hagita H; Takada M; Ayabe M; Aso Y; Ishigai M; Ikeda S
J Pharmacol Exp Ther; 2013 Apr; 345(1):52-61. PubMed ID: 23386251
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
Fushimi N; Fujikura H; Shiohara H; Teranishi H; Shimizu K; Yonekubo S; Ohno K; Miyagi T; Itoh F; Shibazaki T; Tomae M; Ishikawa-Takemura Y; Nakabayashi T; Kamada N; Ozawa T; Kobayashi S; Isaji M
Bioorg Med Chem; 2012 Nov; 20(22):6598-612. PubMed ID: 23062824
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice.
Honda Y; Ozaki A; Iwaki M; Kobayashi T; Nogami A; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Yoneda M; Saito S; Nagashima Y; Nakajima A
J Pharmacol Sci; 2021 Oct; 147(2):176-183. PubMed ID: 34384565
[TBL] [Abstract][Full Text] [Related]
18. C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.
Koga Y; Sakamaki S; Hongu M; Kawanishi E; Sakamoto T; Yamamoto Y; Kimata H; Nakayama K; Kuriyama C; Matsushita Y; Ueta K; Tsuda-Tsukimoto M; Nomura S
Bioorg Med Chem; 2013 Sep; 21(17):5561-72. PubMed ID: 23809172
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.
Yao CH; Song JS; Chen CT; Yeh TK; Hsieh TC; Wu SH; Huang CY; Huang YL; Wang MH; Liu YW; Tsai CH; Kumar CR; Lee JC
Eur J Med Chem; 2012 Sep; 55():32-8. PubMed ID: 22818040
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H
Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
